A humanized LIF-targeting antibody synergistically enhances chemo- and immunotherapy in pancreatic cancer.
1/5 보강
[BACKGROUND] Pancreatic cancer is associated with a low survival rate due to its late diagnosis, and the patients’ resistance to chemotherapy and immunotherapy.
APA
Xu F, Liu W, et al. (2026). A humanized LIF-targeting antibody synergistically enhances chemo- and immunotherapy in pancreatic cancer.. Journal of translational medicine, 24(1). https://doi.org/10.1186/s12967-026-07723-z
MLA
Xu F, et al.. "A humanized LIF-targeting antibody synergistically enhances chemo- and immunotherapy in pancreatic cancer.." Journal of translational medicine, vol. 24, no. 1, 2026.
PMID
41634799
Abstract
[BACKGROUND] Pancreatic cancer is associated with a low survival rate due to its late diagnosis, and the patients’ resistance to chemotherapy and immunotherapy. Leukemia inhibitory factor (LIF), a member of the interleukin-6 (IL-6) cytokine family, promotes the development and progression of pancreatic cancer and has emerged as a promising therapeutic target. Here, our objectives were to validate the druggability of LIF as a therapeutic target and establish an innovative treatment strategy for pancreatic ductal adenocarcinoma (PDAC) by leveraging antibody-mediated LIF blockade to enhance the efficacy of gemcitabine-based chemotherapy or PD-1-targeted immunotherapy.
[METHOD] We generated a humanized anti-LIF antibody using a murine framework as the basis. To minimize immunogenicity, we performed structural optimization of VL/VH domains and employed rational design strategies. Surface plasmon resonance (SPR) was used to determine the binding affinity of the antibody for the LIF antigen. Antitumor efficacy was evaluated across multiple preclinical models, including cancer cell lines, patient-derived organoids (PDOs), cell-derived xenografts（CDXs）, and patient-derived organoid xenografts (PDOXs). The humanized anti-LIF (h-anti-LIF) antibody was co-administered with either chemotherapy or immunotherapy in these models to assess the impact of the combination on tumor growth.
[RESULTS] The h-anti-LIF antibody demonstrated higher specificity and affinity for LIF compared with its murine counterpart and exhibited superior efficacy in inhibiting tumor growth relative to the murine antibody. Furthermore, our findings revealed that selective targeting of LIF not only enhanced the chemosensitivity of pancreatic cancer to gemcitabine but also improved the efficacy of PD-1-targeted immunotherapy.
[CONCLUSION] Our study demonstrates that the humanized anti-LIF antibody emerges as a promising adjuvant for enhancing the efficacy of both chemotherapy and immunotherapy in pancreatic cancer.
[SUPPLEMENTARY INFORMATION] The online version contains supplementary material available at 10.1186/s12967-026-07723-z.
[METHOD] We generated a humanized anti-LIF antibody using a murine framework as the basis. To minimize immunogenicity, we performed structural optimization of VL/VH domains and employed rational design strategies. Surface plasmon resonance (SPR) was used to determine the binding affinity of the antibody for the LIF antigen. Antitumor efficacy was evaluated across multiple preclinical models, including cancer cell lines, patient-derived organoids (PDOs), cell-derived xenografts（CDXs）, and patient-derived organoid xenografts (PDOXs). The humanized anti-LIF (h-anti-LIF) antibody was co-administered with either chemotherapy or immunotherapy in these models to assess the impact of the combination on tumor growth.
[RESULTS] The h-anti-LIF antibody demonstrated higher specificity and affinity for LIF compared with its murine counterpart and exhibited superior efficacy in inhibiting tumor growth relative to the murine antibody. Furthermore, our findings revealed that selective targeting of LIF not only enhanced the chemosensitivity of pancreatic cancer to gemcitabine but also improved the efficacy of PD-1-targeted immunotherapy.
[CONCLUSION] Our study demonstrates that the humanized anti-LIF antibody emerges as a promising adjuvant for enhancing the efficacy of both chemotherapy and immunotherapy in pancreatic cancer.
[SUPPLEMENTARY INFORMATION] The online version contains supplementary material available at 10.1186/s12967-026-07723-z.
같은 제1저자의 인용 많은 논문 (5)
- Association of genetically determined plasma hepatocyte growth factor with lung cancer and its subtypes: Mendelian randomization and mediation analysis.
- Integrated multi-omics profiling to dissect the development of second primary lung cancer in laryngeal cancer: An observational study.
- Correction to "Enrichment and Detection of HER2-Expressing Extracellular Vesicles Based on DNA Tetrahedral Nanostructures: A New Strategy for Liquid Biopsy in Breast Cancer".
- Calcium overloaded multifunctional composite nanomaterials synergistically treat cancer by ferroptosis pathway.
- Editorial for "Development and Deployment of a Machine Learning Model to Triage the Use of Prostate MRI (ProMT-ML) in Patients With Suspected Prostate Cancer".